Literature DB >> 22778822

GlyT1 - Up from the Ashes. The importance of not condemning a mechanism based on a single chemotype.

Craig Lindsley.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 22778822      PMCID： PMC3368659          DOI： 10.1021/cn100017a

Source DB:  PubMed          Journal:  ACS Chem Neurosci        ISSN： 1948-7193            Impact factor:   4.418


× No keyword cloud information.
  6 in total

Review 1.  NMDA receptor hypofunction model of schizophrenia.

Authors:  J W Olney; J W Newcomer; N B Farber
Journal:  J Psychiatr Res       Date:  1999 Nov-Dec       Impact factor: 4.791

2.  Progress in the preparation and testing of glycine transporter type-1 (GlyT1) inhibitors.

Authors:  Craig W Lindsley; Scott E Wolkenberg; Gene G Kinney
Journal:  Curr Top Med Chem       Date:  2006       Impact factor: 3.295

Review 3.  Progress towards validating the NMDA receptor hypofunction hypothesis of schizophrenia.

Authors:  Craig W Lindsley; William D Shipe; Scott E Wolkenberg; Cory R Theberge; David L Williams; Cyrille Sur; Gene G Kinney
Journal:  Curr Top Med Chem       Date:  2006       Impact factor: 3.295

Review 4.  Design of potent GlyT1 inhibitors: in vitro and in vivo profiles.

Authors:  Thomas M Bridges; Richard Williams; Craig W Lindsley
Journal:  Curr Opin Mol Ther       Date:  2008-12

Review 5.  Recent advances in the phencyclidine model of schizophrenia.

Authors:  D C Javitt; S R Zukin
Journal:  Am J Psychiatry       Date:  1991-10       Impact factor: 18.112

Review 6.  N-methyl-D-aspartate receptor-coupled glycineB receptors in the pathogenesis and treatment of schizophrenia: a critical review.

Authors:  M J Millan
Journal:  Curr Drug Targets CNS Neurol Disord       Date:  2002-04
  6 in total
  2 in total

1.  Prepulse inhibition of the startle reflex and response to antipsychotic treatments in two outbred mouse strains in comparison to the inbred DBA/2 mouse.

Authors:  Dorothy G Flood; Eva Zuvich; Michael J Marino; Maciej Gasior
Journal:  Psychopharmacology (Berl)       Date:  2011-02-08       Impact factor: 4.530

2.  Reversible inhibition of the glycine transporter GlyT2 circumvents acute toxicity while preserving efficacy in the treatment of pain.

Authors:  A Mingorance-Le Meur; P Ghisdal; B Mullier; P De Ron; P Downey; C Van Der Perren; V Declercq; S Cornelis; M Famelart; J Van Asperen; E Jnoff; J P Courade
Journal:  Br J Pharmacol       Date:  2013-11       Impact factor: 8.739
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.